Global Blood Therapeutics, Inc. GBT announced that the FDA has approved its lead product candidate Oxbryta (voxelotor) as an oral, once-daily treatment for sickle cell disease (SCD) in patients aged ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback